



# ASX Announcement

**For immediate release**

17 July 2019

## **Anjana Narain to Lead Seqirus Influenza Vaccines Business**

CSL Limited today named Ms Anjana Narain, a seasoned leader in vaccines and biopharmaceuticals, as Executive Vice President and General Manager of its Seqirus business, one of the world's largest influenza vaccines providers, effective 1 August.

She will replace Gordon Naylor, who announced his retirement earlier this year.

"In leading Seqirus, Anjana brings diverse, broad-based experiences as a well-established global industry leader," said CSL CEO & Managing Director Mr. Paul Perreault. "Anjana has focused on protecting public health throughout her career which will be important in continuing to advance Seqirus' differentiated technologies and further grow its market reach. I look forward to working with Anjana and the rest of our management team in executing our strategy and continuing to sustainably grow our global business."

Narain, 52, has a track record of strategic vision and strong leadership that has delivered industry-leading performance and sustainable growth. Narain has extensive global experience, living and working across three continents including North America, Europe and Asia. She brings 27 years of experience with major pharmaceutical companies such as GSK, Merck, and Bayer.

For nine years, Narain led major businesses at GSK including global influenza commercialisation, US respiratory biologics and general management of vaccines, primary care and HIV. She was a member of the global vaccines commercial leadership team and the intercontinental leadership team. At Merck, Narain held progressive leadership roles in the US and global biopharmaceuticals and vaccines. She started her career at Miles (now Bayer) in the US. Her leadership in inclusion and diversity and building a strong talent pipeline has received industry peer recognition.

Narain is a graduate of the Harvard Business School's General Management Program and has served on several industry association boards. She earned her Bachelor of Arts in English from RG College in India

and her Masters of Business Administration from the University of New Haven in the US.

“As a global leader in influenza prevention, Seqirus is well positioned to deliver sustainable growth,” said Narain. “I am excited to lead an organisation that is on the front line in protecting public health around the world.”

### **About CSL**

CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 60 countries and employs more than 22,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information about CSL Limited, visit [www.csl.com](http://www.csl.com).

### **About Seqirus**

Seqirus is part of CSL Limited (ASX:CSL), headquartered in Melbourne, Australia. The CSL Group of companies employs more than 22,000 people with operations in more than 60 countries.

Seqirus was established on 31 July 2015 following CSL’s acquisition of the Novartis influenza vaccines business and its subsequent integration with bioCSL. As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. Seqirus operates state-of-the-art production facilities in the U.S., the UK and Australia, and manufactures influenza vaccines using both egg-based and cell-based technologies. It has leading R&D capabilities, a broad portfolio of differentiated products and a commercial presence in more than 20 countries.



# ASX Announcement

---

Page 3

17 July 2019

For more information visit [www.seqirus.com](http://www.seqirus.com).

**For further information, please contact:**

**Investors:**

Bernard Ronchi  
Senior Manager, Investor Relations  
Phone: +61 393 893 470  
Email: [Bernard.Ronchi@csl.com.au](mailto:Bernard.Ronchi@csl.com.au)

**Media:**

Jemimah Brennan  
Head of Communications, Asia Pacific  
Phone: +61 412 635 483  
Email: [Jemimah.Brennan@csl.com.au](mailto:Jemimah.Brennan@csl.com.au)